Abstract

BackgroundIn clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control. Typically, evidence in each of these paradigms is quantified with a variant of the null hypothesis significance test. A null hypothesis is assumed (null effect, inferior by a specific amount, inferior by a specific amount and superior by a specific amount, for superiority, non-inferiority, and equivalence respectively), after which the probabilities of obtaining data more extreme than those observed under these null hypotheses are quantified by p-values. Although ubiquitous in clinical testing, the null hypothesis significance test can lead to a number of difficulties in interpretation of the results of the statistical evidence.MethodsWe advocate quantifying evidence instead by means of Bayes factors and highlight how these can be calculated for different types of research design.ResultsWe illustrate Bayes factors in practice with reanalyses of data from existing published studies.ConclusionsBayes factors for superiority, non-inferiority, and equivalence designs allow for explicit quantification of evidence in favor of the null hypothesis. They also allow for interim testing without the need to employ explicit corrections for multiple testing.

Highlights

  • In clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control

  • In clinical trials, study designs may focus on assessment of superiority, equivalence, or non-inferiority of a new medicine or other intervention as compared to some control intervention [1, 2]

  • The Bayes factor allows for explicit quantification of evidence in favor of the null hypothesis, which means that the interpretational pitfalls associated with non-inferiority and equivalence designs naturally disappear

Read more

Summary

Introduction

Study designs may focus on assessment of superiority, equivalence, or non-inferiority, of a new medicine or treatment as compared to a control. Evidence in each of these paradigms is quantified with a variant of the null hypothesis significance test. Conclusions: Bayes factors for superiority, non-inferiority, and equivalence designs allow for explicit quantification of evidence in favor of the null hypothesis. They allow for interim testing without the need to employ explicit corrections for multiple testing. Study designs may focus on assessment of superiority, equivalence, or non-inferiority of a new medicine or other intervention as compared to some control intervention [1, 2].

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.